Bioniche Animal Health has announced that its equine joint product, NexHA, has been approved by the United States Food and Drug Administration (FDA) and is now available to U.S. veterinarians.

NexHA is a purified hyaluronate sodium formulation that can be administered by intravenous or intra-articular injection, Bioniche said. The generic drug is FDA-approved for the treatment of joint dysfunction of the carpus (knee) or fetlock in horses that is caused by non-infectious synovitis or osteoarthritis.

Hyaluronic acid is a natural articular cartilage and synovial fluid component in horses. In joints affected by synovitis or osteoarthritis, the presence of HA is reduced.

NexHA is available in a 4-mililiter (40-miligram) vial for an intravenous injection. It is a clear, colorless, sterile, preservative-free, low-viscosity solution, Bioniche said.

Stay on top of the most recent Horse Health news with FREE weekly newsletters from Learn More

Free Newsletters

Sign up for the latest in:

From our partners